Skip to main content
Premium Trial:

Request an Annual Quote

Prenetics Acquires Coronavirus Test Developer Oxsed

NEW YORK — Genetic testing firm Prenetics said on Friday that it has acquired Oxsed, a University of Oxford spinout that was founded to develop and launch a rapid test for SARS-CoV-2.

The Oxsed RaViD Direct test uses reverse-transcription, loop-mediated isothermal amplification to detect SARS-CoV-2 RNA in nasopharyngeal swabs, oropharyngeal swabs, as well as saliva and mouthwash specimens, and provides results in about 30 minutes. Developed by researchers from the University of Oxford and the Oxford Suzhou Centre for Advanced Research, the CE-marked test has demonstrated between 92 percent and 100 percent sensitivity and 100 percent specificity in clinical testing.

Under the terms of the acquisition, Oxsed will continue to focus on prioritizing test access for low- and middle-income countries. Oxford University Innovation, the university's research commercialization arm, will also maintain management rights to Oxsed's license to the testing technology in order to ensure the company's social mission.

Additional terms were not disclosed.

Hong Kong-based Prenetics said that the test is already in use for predeparture testing at London Heathrow airport where the company has set up a rapid testing facility. Prenetics said that it has also set up a semi-automated lab at Hong Kong International Airport to test arriving passengers with the goal of establishing a travel bubble between Singapore and Hong Kong.

Prenetics said that it is in discussions with other international airports about using the test.

"This is truly a game-changer and we aim to make the technology available to millions of people globally," Prenetics Cofounder and CEO Danny Yeung said in a statement. "Rapid, accurate, and frequent testing is one of our most important interventions to prevent large outbreaks and for the global economy."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.